Abstract
Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Current Molecular Medicine
Title:Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Volume: 12 Issue: 10
Author(s): S. Arora, S. Singh, G.A. Piazza, C.M. Contreras, J. Panyam and A.P. Singh
Affiliation:
Keywords: Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma
Abstract: Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
Export Options
About this article
Cite this article as:
Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J. and Singh A.P., Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833508
DOI https://dx.doi.org/10.2174/156652412803833508 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Magnetic and Gold-Coated Magnetic Iron Oxide Nanoparticles as Detection Tools: Preparation, Characterization, and Biosensing Applications
Current Nanoscience Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?
Current Cancer Drug Targets Genome-Wide Analysis of Low Dose Bisphenol-A (BPA) Exposure in Human Prostate Cells
Current Genomics Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays
Anti-Cancer Agents in Medicinal Chemistry New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Tumor Initiation in Human Malignant Melanoma and Potential Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Current Signal Transduction Therapy Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews A Cross Sectional Study of Tumors Using Bio-Medical Imaging Modalities
Current Medical Imaging Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Crystallographic Study and Biological Evaluation of 1,4-dimethyl-<i>N</i>-alkylcarbazoles†
Current Topics in Medicinal Chemistry Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Stability Studies on Piroxicam Encapsulated Niosomes
Current Drug Delivery Editorial [Hot Topic: Plants as Sources of Therapeutic Proteins (Executive Editor: Schuyler S. Korban)]
Current Pharmaceutical Design Identification of Novel Sesamol Dimers with Unusual Methylenedioxy Ring-Opening Skeleton and Evaluation of Their Antioxidant and Cytotoxic Activities
Current Organic Synthesis Editorial (Thematic Issue: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics)
Current Vascular Pharmacology